Kobayashi Pharmaceutical Co., Ltd.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Kobayashi Pharmaceutical Co., Ltd.'s yearly results (2022–2025), compared with Consumer Defensive companies in Japan. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 80.2 times by its yearly operating cash. Higher than 95% of Consumer Defensive companies in Japan.
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Consumer Defensive companies in Japan.
Where ¥100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
¥162Over the last 3 years, every ¥100 of reported profit came with ¥162 of operating cash.
Higher than 56% of Consumer Defensive companies in Japan.
Self-Funding Ratio
1.0×Over the last 3 years its own operating cash covered its investment spending (capex) 1.0 times.
Lower than 77% of Consumer Defensive companies in Japan.
Cash Locked Ratio
¥20For every ¥100 of sales, ¥20 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥19 tied up three years earlier.
More money tied up than 75% of Consumer Defensive companies in Japan.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Consumer Defensive companies in Japan.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by -0% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
-0% / +8%In 3 years sales changed by -0% while total assets changed by +8%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
80.2×Debt due within a year is covered 80.2 times by its yearly operating cash.
Higher than 95% of Consumer Defensive companies in Japan.
Cash Cushion Ratio
+13%Cash, after subtracting all debt, equals 13% of its market value (net cash).
Higher than 66% of Consumer Defensive companies in Japan.
Tangible Assets Ratio
94%Of every ¥100 the company owns, ¥94 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 82% of Consumer Defensive companies in Japan.
Tangible Net Worth Ratio
92%Of every ¥100 of net worth, ¥92 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 74% of Consumer Defensive companies in Japan.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Kobayashi Pharmaceutical Co., Ltd. owes ¥0.17 for every ¥1 it owns. Net profit fell 64% in the year to Dec 2025, and shrank 43% a year on average over 3 years.
Compared with Consumer Defensive companies in Japan · latest annual results Dec 2025.
P/E ratio
322.3Investors pay ¥322.3 for every ¥1 of Kobayashi Pharmaceutical Co., Ltd.'s yearly profit, higher than almost all Consumer Defensive companies in Japan.
P/B ratio
2.46The share price is 2.46 times Kobayashi Pharmaceutical Co., Ltd.'s book value per share, higher than 85% of Consumer Defensive companies in Japan.
Market cap
¥514.9 BThe total market value of all of Kobayashi Pharmaceutical Co., Ltd.'s shares at today's price (share price × number of shares), larger than 91% of Consumer Defensive companies in Japan. PosiCap size class: Meso Cap.
Net worth (book value)
¥209.7 BWhat Kobayashi Pharmaceutical Co., Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
¥2,821Net worth divided by the number of shares. The share price of ¥6,927 is 2.5 times this, which is the P/B above.
Return on equity (ROE)
0.8%Kobayashi Pharmaceutical Co., Ltd. earned 0.8% on its shareholders' money over the last year, lower than 90% of Consumer Defensive companies in Japan.
Owes vs Owns
0.17×Kobayashi Pharmaceutical Co., Ltd. owes ¥0.17 for every ¥1 it owns (low), lower than 94% of Consumer Defensive companies in Japan.
Dividend yield
1.48%Kobayashi Pharmaceutical Co., Ltd. pays 1.48% of its share price as dividends a year, lower than 79% of dividend-paying Consumer Defensive companies in Japan.
Revenue growth
+0%Revenue rose 0% in the year to Dec 2025, and shrank 0% a year on average over 3 years.
Profit growth
-64%Net profit fell 64% in the year to Dec 2025, and shrank 43% a year on average over 3 years.
Profit margin
2.2%Kobayashi Pharmaceutical Co., Ltd. keeps ¥2 of every ¥100 of revenue as net profit.
Cash quality
7.0×Cash from Kobayashi Pharmaceutical Co., Ltd.'s business was 7.0× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
533.1×Kobayashi Pharmaceutical Co., Ltd.'s operating profit covered its interest costs 533.1 times in the year to Dec 2025.
Cash vs debt
Net cashKobayashi Pharmaceutical Co., Ltd. held ¥69.9 B more cash than debt (net cash) at Dec 2025.
Questions
What is Kobayashi Pharmaceutical Co., Ltd.'s P/E ratio?
Investors pay ¥322.3 for every ¥1 of Kobayashi Pharmaceutical Co., Ltd.'s yearly profit, higher than almost all Consumer Defensive companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Kobayashi Pharmaceutical Co., Ltd.: ¥514.9 B ÷ ¥209.7 B (30 Jun 2026) = 2.5.
What is Kobayashi Pharmaceutical Co., Ltd.'s return on equity?
Kobayashi Pharmaceutical Co., Ltd. earned 0.8% on its shareholders' money over the last year, lower than 90% of Consumer Defensive companies in Japan.
How much does Kobayashi Pharmaceutical Co., Ltd. owe compared with what it owns?
Kobayashi Pharmaceutical Co., Ltd. owes ¥0.17 for every ¥1 it owns (low), lower than 94% of Consumer Defensive companies in Japan.
Does Kobayashi Pharmaceutical Co., Ltd. pay a dividend?
Yes. Kobayashi Pharmaceutical Co., Ltd. pays 1.48% of its share price as dividends a year, lower than 79% of dividend-paying Consumer Defensive companies in Japan.
Is Kobayashi Pharmaceutical Co., Ltd.'s revenue growing?
Revenue rose 0% in the year to Dec 2025, and shrank 0% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.